Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7486 AL 7500

Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity

Zhang Y, Chen J, Li Y, Jiao B, Luo S.

Ageing Res Rev. 2025 Jan;103:102595. doi: 10.1016/j.arr.2024.102595. Epub 2024 Nov 22.

Recent Studies on Heterocyclic Cholinesterase Inhibitors Against Alzheimer's Disease

Tok F.

Chem Biodivers. 2025 Apr;22(4):e202402837. doi: 10.1002/cbdv.202402837. Epub 2024 Dec 3.

The immunomodulatory effects of psychedelics in Alzheimer's disease-related dementia

Mohammad Hosseini A, Khaleghzadeh-Ahangar H, Rahimi A.

Neuroscience. 2025 Jan 9;564:271-280. doi: 10.1016/j.neuroscience.2024.11.062. Epub 2024 Nov 26.

Shedding light on microglial dysregulation in Alzheimer's disease: exploring molecular mechanisms and therapeutic avenues

Bhardwaj V, Kumari S, Dhapola R, Sharma P, Beura SK, Singh SK, Vellingiri B, HariKrishnaReddy D.

Inflammopharmacology. 2025 Feb;33(2):679-702. doi: 10.1007/s10787-024-01598-6. Epub 2024 Nov 28.

Deoxyvasicinone hybrids in the management of Alzheimer's disease: Recent advances on manmade derivatives, pharmacological activities, and structure-activity relationship

Gaur A, Singh YP, Sharma R, Bainsal N.

Arch Pharm (Weinheim). 2025 Jan;358(1):e2400742. doi: 10.1002/ardp.202400742.

Prospective Utilization of Nanocarriers Loaded with Drug Combination for Treating Alzheimer's Disease

Khan SA, Qamar Z, Rohilla A, Singh PP, Parvez S, Baboota S, Ali J.

Curr Pharm Des. 2025;31(18):1444-1460. doi: 10.2174/0113816128348877241202053633.

Design, current states, and challenges of nanomaterials in anti-neuroinflammation: A perspective on Alzheimer's disease

Hong X, Chen T, Liu Y, Li J, Huang D, Ye K, Liao W, Wang Y, Liu M, Luan P.

Ageing Res Rev. 2025 Mar;105:102669. doi: 10.1016/j.arr.2025.102669. Epub 2025 Jan 27.

Mitochondrial dysfunction in Alzheimer's disease: a key frontier for future targeted therapies

Wang S, Liao Z, Zhang Q, Han X, Liu C, Wang J.

Front Immunol. 2025 Jan 14;15:1484373. doi: 10.3389/fimmu.2024.1484373. eCollection 2024.

Uncovering the intricacies of IGF-1 in Alzheimer's disease: new insights from regulation to therapeutic targeting

Kaur N, Aran KR.

Inflammopharmacology. 2025 Mar;33(3):1311-1330. doi: 10.1007/s10787-025-01641-0. Epub 2025 Jan 30.

Melatonin Overexpression in the Management of Alzheimer's Disease: Therapeutic Exploration

Gupta B, Malviya R, Sundram S, Sridhar SB, Singh DP.

Curr Top Med Chem. 2025;25(15):1783-1794. doi: 10.2174/0115680266327614241121050448.

Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research

Smith EE, Phillips NA, Feldman HH, Borrie M, Ganesh A, Henri-Bhargava A, Desmarais P, Frank A, Badhwar A, Barlow L, Bartha R, Best S, Bethell J, Bhangu J, Black SE, Bocti C, Bronskill SE, Burhan AM, Calon F, Camicioli R, Campbell B, Collins DL, Dadar M, DeMarco ML, Ducharme S, Duchesne S, Einstein G, Fisk JD, Gawryluk JR, Grossman L, Ismail Z, Itzhak I, Joshi M, Harrison A, Kröger E, Kumar S, Laforce R, Lanctot KL, Lau M, Lee L, Masellis M, Massoud F, Mitchell SB, Montero-Odasso M, Myers Barnett K, Nygaard HB, Pasternak SH, Peters J, Rajah MN, Robillard JM, Rockwood K, Rosa-Neto P, Seitz DP, Soucy JP, Trenaman SC, Wellington CL, Zadem A, Chertkow H; Canadian Consortium on Neurodegeneration in Aging Investigators.

J Prev Alzheimers Dis. 2025 Mar;12(3):100068. doi: 10.1016/j.tjpad.2025.100068. Epub 2025 Jan 31.

Improvements in Exercise for Alzheimer's Disease: Highlighting FGF21-Induced Cerebrovascular Protection

Wang J, Meng X, Yang J, Tang Y, Zeng F, Wang Y, Chen Z, Chen D, Zou R, Liu W.

Neurochem Res. 2025 Feb 4;50(2):95. doi: 10.1007/s11064-025-04350-w.

Lipoic acid scaffold applications in the design of multitarget-directed ligands against Alzheimer's disease

Manavi MA, Nourhashemi M, Emami S, Fathian Nasab MH, Dehnavi F, Küçükkılınç TT, Foroumadi A, Sharifzadeh M, Khoobi M.

Bioorg Chem. 2025 Apr;157:108241. doi: 10.1016/j.bioorg.2025.108241. Epub 2025 Feb 3.

Understanding of Alzheimer's disease pathophysiology for therapeutic implications of natural products as neuroprotective agents

Prabha S, Choudhury A, Islam A, Thakur SC, Hassan MI.

Ageing Res Rev. 2025 Mar;105:102680. doi: 10.1016/j.arr.2025.102680. Epub 2025 Feb 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias